Our experiments revealed that knocking out METTL3 in glioblastoma cell lines (U87-MG, U251) and primary glioma cells (GBM85) or knocking down METTL3 in non-small cell lung cancer (NSCLC) cell lines (A549, H1299) and breast cancer cell lines (MDA-MB-231, LM2) led to a reduction in EGFR protein levels without affecting its mRNA levels (Figures 5A, 5B, S5A, and S5B). The gene discussed is METTL3; the disease is central nervous system cancer.